What is ACTU's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ACTU?

P/E (TTM) is n/a and 52-week range is $0.60 to $8.49 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ACTU figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ACTU?

The company profile lists net income (TTM) near $-21M, EPS (TTM) near $-0.89 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Actuate Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Fort Worth, Texas, US, 23.9M shares outstanding, ISIN US0050831009 when available from company profile and filing metadata.

Actuate Therapeutics Inc (ACTU) Stock Analysis & Quote

Actuate Therapeutics Inc

$ACTU

Health Care · Biotechnology

IR Run Scenarios

$0.61

-10.13%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. The company is headquartered in Fort Worth, Texas and currently employs 12 full-time employees. The company went IPO on 2024-08-13. The firm is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The firm is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.

Employees

Website

actuatetherapeutics.com/

IPO

2024-08-13

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)